Population-Scale Genomic Profiling: Toward Personalized Prediction of Aging Trajectories

1. Introduction: Measuring Aging Before It Shows

Chronological age is a poor predictor of individual health. Two people of the same age may differ by decades in physiological function, frailty, and remaining life expectancy, because aging is a heterogeneous process shaped by genetics, environment, behaviour, and chance. Population-scale genomic profiling — sequencing or genotyping hundreds of thousands of volunteers and linking their DNA to lifelong health records — is an attempt to decompose that heterogeneity. Its premise is that biological age is at least partly measurable, that part of it is heritable, and that measurable and heritable risk can be acted upon before disease appears.

This article distinguishes four distinct claims that are frequently bundled together: that genomes predict disease risk (partly established); that specific genetic variants cause or protect against disease (established in some cases); that polygenic and multi-omic scores improve health outcomes when used clinically (emerging, with limited randomised evidence); and that genome-scale screening will meaningfully extend lifespan (hypothesis). The infrastructure is real and maturing; the clinical payoff is uneven and, in several respects, unproven.

2. The Data Infrastructure: Biobanks and Population Genomic Cohorts

Population genomics depends on two resources that did not exist at scale two decades ago: large, deeply phenotyped cohorts, and inexpensive high-throughput sequencing. Together they convert aging from a uniform demographic fate into a set of individually measurable trajectories.

2.1. The Major Cohorts

• UK Biobank. Approximately 500,000 participants aged 40-69 were recruited between 2006 and 2010 and followed through linked hospital records, primary care, cancer and death registries, imaging, proteomics, and metabolomics. Most were initially genotyped on SNP arrays and imputed to tens of millions of variants; whole-exome sequencing followed. In 2025 the UK Biobank Whole-Genome Sequencing Consortium reported whole-genome sequencing of 490,640 participants at an average coverage of 32.5×, yielding roughly 1.5 billion identified variants — an 18.8-fold increase in observed variation over imputed array data and more than a 40-fold increase over whole-exome data.
• All of Us (United States). A National Institutes of Health program explicitly designed to over-represent populations historically under-represented in biomedical research, with electronic health records, surveys, wearable data, and genomic data. Its reported enrolment passed 830,000 participants, with data available for research on several hundred thousand, as of the program’s 2025-2026 milestones.
• National and international initiatives. Genome projects in the United Kingdom (Genomics England), Estonia, Japan, Finland, China, and elsewhere, together with long-running reference resources such as the 1000 Genomes Project, provide the diversity of genetic backgrounds against which any ageing-related prediction must be validated.

2.2. What Whole-Genome Sequencing Adds Over Genotyping

SNP arrays and imputation accurately capture common variants but are poorly suited to rare variants and to structurally complex regions of the genome. Whole-exome sequencing covers the coding 2-3% of the genome but omits nearly all non-coding variation and detects structural variants inconsistently. Whole-genome sequencing addresses both gaps, which matters for aging research because much of the genetic architecture of common diseases — and presumably of complex traits such as biological age — involves non-coding regulatory variation. The practical consequence is that rare, large-effect protective variants, of the kind that can point directly to drug targets, are more likely to be discovered in whole-genome data than in array data.

3. What Population Genomics Has Established About Aging

3.1. Polygenic Risk Scores: Established Prediction, Contested Utility

A polygenic risk score (PRS) aggregates the small effects of many hundreds to millions of variants into a single number that estimates an individual’s genetic liability for a trait. For coronary artery disease, type 2 diabetes, breast and prostate cancer, and Alzheimer’s disease, well-validated scores can identify individuals whose risk is several-fold higher than average, and in some analyses a small high-score fraction carries risk comparable to that of monogenic conditions. This discriminative performance is established.

What is weaker is clinical utility. A score that stratifies risk does not automatically improve outcomes; that requires evidence that acting on the score prevents disease better than acting on conventional risk factors. For most conditions, randomised trials of PRS-guided care are still limited, and the incremental information over family history and clinical risk calculators is often modest. PRS also has two structural weaknesses: it transfers poorly across ancestries, because most discovery cohorts have been of European descent (the overwhelming majority of genome-wide association study participants to date), and it is a probabilistic statement about a population, not a deterministic prediction for an individual.

3.2. Longevity Genetics and the Heritability Debate

Human lifespan is heritable, but the extent is smaller and more contested than popular accounts suggest. Estimates from twin studies commonly place the genetic contribution at roughly a quarter, but at least one influential reanalysis argued that much of this apparent heritability is inflated by assortative mating (people tending to partner with genetically similar people), giving a substantially lower estimate. The robust longevity-associated loci include APOE — whose ε4 allele also affects Alzheimer’s and cardiovascular risk — and FOXO3, with additional signals emerging from large meta-analyses. Individual effect sizes are small; no common variant confers more than a modest change in the odds of exceptional survival.

Where genetics has delivered a therapy rather than a risk estimate, it has done so through rare, large-effect variants that revealed a druggable target. Loss-of-function variants in PCSK9, associated with lifelong low LDL cholesterol and reduced coronary risk, motivated the PCSK9 inhibitors now in clinical use. This is the clearest demonstration that human longevity-associated genetics can yield therapeutics, and it explains why rare-variant discovery, rather than common-variant scoring, is the more promising route to new drugs.

3.3. Pharmacogenomics: An Established Model of Personalised Prevention

Pharmacogenomics is the most mature form of genetically personalised medicine and an instructive model for personalised aging. Well-established examples include HLA-B*57:01 screening to prevent abacavir hypersensitivity, HLA-B*15:02 and related alleles for carbamazepine-related severe skin reactions, CYP2C19 genotype for clopidogrel activation, SLCO1B1 genotype for statin-associated myopathy, and DPYD variants for fluoropyrimidine toxicity. These are not longevity interventions, but they demonstrate the principle that a genetic test can change a clinical decision and prevent harm — the standard to which other forms of genomic profiling must aspire.

3.4. Multi-Omic and Biological-Age Clocks

DNA alone captures only one layer of biological age. Epigenetic clocks, based on patterns of DNA methylation, estimate age from a tissue sample and predict mortality better than chronological age; second-generation clocks and composite measures aim to capture physiological rather than merely chronological age. In parallel, large-scale plasma proteomics — in which thousands of circulating proteins are quantified in biobank-scale cohorts — has produced proteomic age scores that predict mortality and organ-specific decline, sometimes more strongly than genetic risk alone. Metabolomic layers add a further dimension.

These multi-omic clocks are emerging tools. Their strengths are predictive performance and the ability to track change over time; their limitations are an unclear causal relationship to aging itself, sensitivity to batch and pre-analytical variation, and the risk that a clock measures disease burden or inflammation rather than aging as a process. A clock that predicts mortality is not automatically a valid endpoint for testing whether an intervention slows aging — a distinction that matters if such clocks are used to evaluate anti-aging therapies.

4. From Prediction to Prevention

The clinical hypothesis is stratified prevention: more intensive lipid control for high polygenic coronary risk, earlier and more frequent screening for genetically elevated cancer risk, tighter glycaemic surveillance for high diabetes risk, and targeted pharmacogenomic prescribing to avoid adverse drug reactions. In principle, combining genetic predisposition with longitudinal biomarker trajectories allows prevention to begin years or decades before overt disease, when intervention is most effective.

The honest caveat is that this logic is largely inferential. Risk stratification demonstrably shifts who is recommended for existing interventions; it is far less clear that genetic stratification produces better outcomes than simply applying those interventions more broadly to people at elevated phenotypic risk. The strongest evidence for precision prevention comes from monogenic conditions (for example, familial hypercholesterolaemia and hereditary cancer syndromes) rather than from polygenic scoring. Extending the model to the general population is an active research question, not an established result.

5. The Limits of Prediction

• Fraction of risk explained. Polygenic scores explain a fraction of liability, never a destiny. Genetic fatalism is as unscientific as genetic hype.
• Ancestry bias. Prediction accuracy degrades for populations under-represented in discovery cohorts — a scientific deficiency and an equity problem that programmes such as All of Us are designed to address.
• Calibration and prevalence. As with any screening test, the meaning of a «high» score depends on the underlying prevalence and on how the score is calibrated; absolute risk, not relative rank, should drive decisions.
• Clinical utility versus discriminative accuracy. A statistically strong association or well-separated risk distribution does not establish that using the test improves health. Formal health-economic and, ideally, randomised evaluation is required.
• Biological-age ambiguity. Multi-omic clocks may track chronological age, cumulative damage, or active disease rather than the rate of aging; treating them as equivalent can mislead both research and consumers.

6. Privacy, Equity, and Governance

Genomes are identifying and immutable: unlike a password, a leaked genome cannot be reissued, and it carries information about relatives who never consented to testing. This makes governance as consequential as sequencing itself. Three issues are central. First, informed participation: large cohorts depend on trust, feedback of clinically actionable findings, and clear limits on secondary use. Second, equity: if the benefits of genomic profiling accrue mainly to well-resourced populations and the reference data remain Eurocentric, precision medicine risks widening existing health disparities rather than narrowing them. Third, commercial and insurance pressure: the value of genomic risk prediction can be distorted by markets for consumer genetic tests and longevity products that outrun the evidence. Governance frameworks that protect participants while enabling research are therefore a scientific requirement, not merely an ethical one.

7. Conclusion

Population-scale genomic profiling has built the reference infrastructure on which personalised prediction of aging will depend: biobanks linking genomes to lifelong health records, whole-genome resources that capture rare and non-coding variation, and multi-omic layers that measure biological state, not just inherited sequence. These are genuine achievements, and the discovery of protective variants that yielded PCSK9 inhibitors shows that this infrastructure can produce therapies, not only risk scores.

Yet the distance between prediction and proven benefit remains wide. Polygenic scores are informative but imperfectly transferable; heritability of lifespan is modest and debated; multi-omic clocks predict but do not yet explain; and clinical utility for most genomic tools remains unproven in randomised terms. The defensible position is that genomic profiling is today a powerful research and risk-stratification instrument with a small number of established clinical applications, and tomorrow’s probable discovery engine for longevity therapeutics — but not yet a validated method of extending human lifespan.

Sources and Key Research Centers

1. UK Biobank Whole-Genome Sequencing Consortium. «Whole-genome sequencing of 490,640 UK Biobank participants.» Nature, 2025; 645: 692-701. DOI: 10.1038/s41586-025-09272-9
2. Sudlow C, Gallacher J, Allen N, et al. «UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age.» PLOS Medicine, 2015; 12(3): e1001779. DOI: 10.1371/journal.pmed.1001779
3. Denny JC, Rutter JL, Goldstein DB, et al. «The ‘All of Us’ Research Program.» New England Journal of Medicine, 2019; 381(7): 668-676. DOI: 10.1056/NEJMsr1809937
4. Khera AV, Chaffin M, Aragam KG, et al. «Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations.» Nature Genetics, 2018; 50(9): 1219-1224. DOI: 10.1038/s41588-018-0183-z
5. Torkamani A, Wineinger NE, Topol EJ. «The personal and clinical utility of polygenic risk scores.» Nature Reviews Genetics, 2018; 19(9): 581-590. DOI: 10.1038/s41576-018-0018-x
6. Sirugo G, Williams SM, Tishkoff SA. «The missing diversity in human genetic studies.» Cell, 2019; 177(1): 26-31. DOI: 10.1016/j.cell.2019.02.048
7. Ruby JG, Wright KM, Rand KA, et al. «Estimates of the heritability of human longevity are substantially inflated due to assortative mating.» Genetics, 2018; 210(3): 1109-1124. DOI: 10.1534/genetics.118.301613
8. Willcox BJ, Donlon TA, He Q, et al. «FOXO3A genotype is strongly associated with human longevity.» PNAS, 2008; 105(37): 13987-13992. DOI: 10.1073/pnas.0801030105
9. Horvath S. «DNA methylation age of human tissues and cell types.» Genome Biology, 2013; 14(10): R115. DOI: 10.1186/gb-2013-14-10-r115
10. Sun BB, Chiou J, Traylor M, et al. «Plasma proteomic associations with genetics and health in the UK Biobank.» Nature, 2023; 622: 329-338. DOI: 10.1038/s41586-023-06592-6
11. Relling MV, Evans WE. «Pharmacogenomics in the clinic.» Nature, 2015; 526(7573): 343-350. DOI: 10.1038/nature15817
12. UK Biobank — approximately 500,000 participants with genomes, imaging, proteomics, and linked health records.
13. NIH All of Us Research Program — diverse U.S. cohort for precision health and genomic research.
14. International Genome Sample Resource (1000 Genomes Project) — global reference of human genetic variation.
15. PGS Catalog — open repository of published polygenic scores, with ancestry and performance annotation. (Lambert SA et al., Nature Genetics, 2021; 53: 420-425. DOI: 10.1038/s41588-021-00783-5)
16. Clinical Pharmacogenetics Implementation Consortium (CPIC) — evidence-based guidelines translating pharmacogenomic variants into prescribing decisions.